clinical trial · NCT07215962
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
Bristol-Myers Squibb·—·active not recruiting·n = 300
Non-small Cell Lung Cancer (NSCLC)Nivolumab + ipilimumabNivolumab + ipilimumab + platinum-based chemotherapyImmuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapyOther dual-immuno-oncology therapy with chemotherapy
brief summary
The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy
started
Nov 22, 2024
primary completion
Jul 1, 2025
completion
Mar 1, 2026
last updated
Oct 14, 2025
official title
Real-World Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Pd-L1 <1% in the Florida Cancer Specialists & Research Institute Database
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol